Condition: Non-small Cell Lung Cancer · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is an immunotherapy treatment which helps the immune system fight cancer. The main purpose of this study is to evaluate whether adjuvant intismeran autogene (V940) in combination with SC pembrolizumab and berahyaluronidase alfa (MK-3475A) or intismeran monotherapy improves disease-free survival (DFS) compared with placebo in participants with completely resected high-risk Stage I NSCLC.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Smilow Cancer Center at Yale-New Haven ( Site 3253) | New Haven, Connecticut, United States | Recruiting |
| Billings Clinic ( Site 3255) | Billings, Montana, United States | Recruiting |
| NHO Revive Research Institute, LLC ( Site 3218) | Lincoln, Nebraska, United States | Recruiting |
| Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207) | Reno, Nevada, United States | Recruiting |
| White Plains Hospital ( Site 3213) | White Plains, New York, United States | Recruiting |
| WakeMed Raleigh Campus ( Site 3214) | Raleigh, North Carolina, United States | Recruiting |
| Altru Health System ( Site 3254) | Grand Forks, North Dakota, United States | Recruiting |
| The University of Tennessee Medical Center ( Site 3223) | Knoxville, Tennessee, United States | Recruiting |
| West Virginia University ( Site 3237) | Morgantown, West Virginia, United States | Recruiting |
| One Clinical Research ( Site 0501) | Nedlands, Western Australia, Australia | Recruiting |
| Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2506) | Hamilton, Ontario, Canada | Recruiting |
| Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2503) | Kingston, Ontario, Canada | Recruiting |
+ 30 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07513376